Literature DB >> 24857275

Prognostic significance of lactate/proton symporters MCT1, MCT4, and their chaperone CD147 expressions in urothelial carcinoma of the bladder.

Jung-Woo Choi1, Younghye Kim1, Ju-Han Lee1, Young-Sik Kim2.   

Abstract

OBJECTIVE: To investigate the prognostic significance of lactate/proton monocarboxylate transporters MCT1, MCT4, and their chaperone CD147 expressions in urothelial carcinoma of the bladder (UCB).
METHODS: We examined the expressions of MCT1, MCT4, and CD147 proteins in a total of 360 cases of UCB by immunohistochemistry. The immunohistochemical expressions were quantified using an ImageJ-based analysis program.
RESULTS: MCT1, MCT4, and CD147 expressions were increased in 130 (36.1%), 168 (46.7%), and 228 (63.3%) UCB cases, respectively. Most tumor cells showed diffuse membranous staining, whereas normal urothelial cells showed negative or weak staining. High levels of MCT1 expression correlated with high World Health Organization grade (P<.001), advanced tumor node metastasis (TNM) stage (P<.001), nonpapillary growth type (P<.001), and lymphatic tumor invasion (P=.010), whereas high levels of MCT4 expression did not significantly correlate with any of these variables. High CD147 expression was associated with high World Health Organization grade (P<.001), advanced tumor node metastatis stage (P<.001), and nonpapillary growth type (P=.003). Univariate analyses revealed that high MCT1 (P<.001) and CD147 (P=.029) expressions were associated with poor overall survival and that high MCT4 expression was correlated with poor recurrence-free survival (P=.036). Multivariate analyses revealed that high MCT1 and MCT4 expressions were independent prognostic factors for poor overall survival and poor recurrence-free survival, respectively, in UCB patients.
CONCLUSION: Our results indicate that increased MCT1, MCT4, and CD147 expressions have prognostic implications in UCB and suggest their roles in urothelial cancer metabolism.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24857275     DOI: 10.1016/j.urology.2014.03.031

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  29 in total

1.  MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4.

Authors:  Candice Sun Hong; Nicholas A Graham; Wen Gu; Carolina Espindola Camacho; Vei Mah; Erin L Maresh; Mohammed Alavi; Lora Bagryanova; Pascal A L Krotee; Brian K Gardner; Iman Saramipoor Behbahan; Steve Horvath; David Chia; Ingo K Mellinghoff; Sara A Hurvitz; Steven M Dubinett; Susan E Critchlow; Siavash K Kurdistani; Lee Goodglick; Daniel Braas; Thomas G Graeber; Heather R Christofk
Journal:  Cell Rep       Date:  2016-02-11       Impact factor: 9.423

2.  Metabolic coupling in urothelial bladder cancer compartments and its correlation to tumor aggressiveness.

Authors:  Julieta Afonso; Lúcio L Santos; António Morais; Teresina Amaro; Adhemar Longatto-Filho; Fátima Baltazar
Journal:  Cell Cycle       Date:  2015-12-04       Impact factor: 4.534

Review 3.  Metabolic coupling and the Reverse Warburg Effect in cancer: Implications for novel biomarker and anticancer agent development.

Authors:  Lindsay Wilde; Megan Roche; Marina Domingo-Vidal; Katherina Tanson; Nancy Philp; Joseph Curry; Ubaldo Martinez-Outschoorn
Journal:  Semin Oncol       Date:  2017-10-10       Impact factor: 4.929

4.  Effect of transforming growth factor-β1 on functional expression of monocarboxylate transporter 1 in alveolar epithelial A549 cells.

Authors:  Mohi Uddin; Masashi Kawami; Ryoko Yumoto; Mikihisa Takano
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-01-03       Impact factor: 3.000

5.  Evaluation of Monocarboxylate Transporter 4 (MCT4) Expression and Its Prognostic Significance in Circulating Tumor Cells From Patients With Early Stage Non-Small-Cell Lung Cancer.

Authors:  Athina Markou; E Tzanikou; G Kallergi; E Pantazaka; V Georgoulias; A Kotsakis; E Lianidou
Journal:  Front Cell Dev Biol       Date:  2021-04-22

Review 6.  Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer.

Authors:  Nicola Antonio di Meo; Davide Loizzo; Savio Domenico Pandolfo; Riccardo Autorino; Matteo Ferro; Camillo Porta; Alessandro Stella; Cinzia Bizzoca; Leonardo Vincenti; Felice Crocetto; Octavian Sabin Tataru; Monica Rutigliano; Michele Battaglia; Pasquale Ditonno; Giuseppe Lucarelli
Journal:  Int J Mol Sci       Date:  2022-04-10       Impact factor: 6.208

Review 7.  The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature.

Authors:  Lijuan Xiong; Carl K Edwards; Lijun Zhou
Journal:  Int J Mol Sci       Date:  2014-09-29       Impact factor: 5.923

Review 8.  CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis.

Authors:  Xiaoyan Xin; Xianqin Zeng; Huajian Gu; Min Li; Huaming Tan; Zhishan Jin; Teng Hua; Rui Shi; Hongbo Wang
Journal:  Sci Rep       Date:  2016-09-09       Impact factor: 4.379

Review 9.  Prognostic Indications of Elevated MCT4 and CD147 across Cancer Types: A Meta-Analysis.

Authors:  Cory D Bovenzi; James Hamilton; Patrick Tassone; Jennifer Johnson; David M Cognetti; Adam Luginbuhl; William M Keane; Tingting Zhan; Madalina Tuluc; Voichita Bar-Ad; Ubaldo Martinez-Outschoorn; Joseph M Curry
Journal:  Biomed Res Int       Date:  2015-12-08       Impact factor: 3.411

10.  Monocarboxylate transporter 1 contributes to growth factor-induced tumor cell migration independent of transporter activity.

Authors:  Alana L Gray; David T Coleman; Runhua Shi; James A Cardelli
Journal:  Oncotarget       Date:  2016-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.